Awards & Advancement

Exco InTouch recognized in Deloitte’s Technology Fast 50 tech awards

Friday, November 18, 2016

Exco InTouch, a provider of digital patient engagement and data capture solutions for clinical research and healthcare providers, has been recognized in Deloitte’s 2016 U.K. Fast 50 technology awards—securing the award in acknowledgment of the rapid growth achieved by the company over the course of the last four years. The accolade recognizes the success of Exco InTouch as the market leader in its field and pioneer of key innovations that have transformed the sector.

[Read More]

Neon Therapeutics appoints Dr. Richard Gaynor to president of R&D

Monday, November 7, 2016

Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, has announced the appointment of Richard Gaynor, M.D., to president of research and development. Dr. Gaynor succeeds interim chief scientific officer Robert Tepper, M.D., a partner at Third Rock Ventures, who is continuing as a member of the company’s board of directors.

[Read More]

Veristat appoints James Roach, M.D. as chief medical officer

Monday, November 7, 2016

Veristat has appointed James (Jim) Roach, M.D., FACP, FCCP as its new chief medical officer to bolster the expansion of its clinical operations, medical and regulatory affairs offerings. Dr. Roach will assume his position of chief medical officer on December 2, 2016. In this role, he will lead and grow the clinical operations, medical writing, medical monitoring, safety/pharmacovigilance and regulatory affairs teams at Veristat.

[Read More]

Halloran Consulting Group expands Regulatory and Development Team

Friday, November 4, 2016

Halloran Consulting Group, a national consultancy guiding life science companies to optimize development and performance, has announced the expansion of its regulatory and development team with the hiring of additional, highly specialized consultants, Iva Toudjarska, Ph.D., MBA, as principal consultant, Amanda Ceres, MS, as senior consultant and Keri Siggers, Ph.D., as consultant II. Earlier this year, Michelle Rose, Ph.D., was hired as principal consultant, to further enhance the company’s ability to deliver regulatory strategies and services.

[Read More]

Oncolytics Biotech President and CEO Brad Thompson steps down

Friday, November 4, 2016

Oncolytics Biotech has announced that Brad Thompson, Ph.D., has stepped down as president and chief executive officer of Oncolytics, effective immediately. The company’s Chief Operating Officer Matt Coffey Ph.D., M.B.A., has been appointed interim president and chief executive officer while the company conducts a search for Dr. Thompson’s replacement.

[Read More]

NIMH’s Francis McMahon awarded Colvin Prize

Wednesday, November 2, 2016

The National Institute of Mental Health (NIMH) has announced that Francis McMahon, M.D., has been named a recipient of the Brain & Behavior Research Foundation’s 2016 Colvin Prize for Outstanding Achievement in Mood Disorders Research. Dr. McMahon is chief of the Human Genetics Branch at NIMH. He came to the Institute in 2002 to establish a new genetics unit within the Intramural Research Program. Dr. McMahon’s mission at NIMH has been the identification of genes that contribute to the risk for mood and anxiety disorders so that better methods of diagnosis and treatment can be developed.

[Read More]

Amgen appoints Ellen J. Kullman to board of directors

Monday, October 24, 2016

Amgen has announced the appointment of Ellen J. Kullman to the Amgen board of directors.  Kullman will serve as a member of the Audit Committee and the Governance and Nominating Committee of the Board. Following the appointment of Ms. Kullman, the Board will comprise 14 directors, 13 of whom are independent.

[Read More]